Whether you survive cancer should never depend on where you were born
Cancer has become one of humanity's most unequal burdens — not because the disease itself discriminates, but because the systems built to treat it do. The World Health Organisation now reports nearly 10 million deaths annually, with projections suggesting the toll could reach 35 million new cases per year by 2050, a crisis shaped less by biology than by geography and wealth. Nigeria, confronting this reality directly, is expanding financial protections and investing in local drug production — a deliberate act of refusal to accept that where one is born should determine whether one survives. The work is slow, the gap is wide, and the choices that created this inequity are the same ones that can, in principle, undo it.
- Cancer kills over 26,000 people every single day, and without urgent intervention, annual new diagnoses will nearly double to 35 million by 2050.
- The survival divide is brutal: a breast cancer patient in a wealthy country has an 87% chance of living five years, while her counterpart in a poor country faces odds of just 42% — the same disease, radically different fates.
- Africa bears a rising share of the global cancer burden yet contributes only 8% of cancer research, leaving the continent simultaneously most exposed and least equipped to respond.
- Nigeria is pushing back — expanding the Catastrophic Health Fund to cover prevention, diagnosis, chemotherapy, and radiotherapy, while offering costly immunotherapy drugs like Nivolumab and Keytruda free through clinical trials.
- The government's strategy aims to domesticate expensive treatments and build local drug manufacturing capacity, so Nigerians no longer need to seek abroad the care they cannot afford at home.
Every day, cancer erases the equivalent of a small city. The World Health Organisation's 2026 Global Status Report, produced with the International Agency for Research on Cancer, confirms what many feared: nearly 10 million people die from the disease each year, with over 20 million new diagnoses annually — a figure projected to climb toward 35 million by 2050. The numbers alone are staggering. But the geography behind them is starker still.
A woman diagnosed with breast cancer in a wealthy country has an 87% chance of surviving five years. In a poor country, that figure falls to 42%. The same disease. Different worlds. Asia carries more than half of all global cases and deaths. Africa and parts of Asia see lower incidence but disproportionately high mortality — the unmistakable signature of populations who fall ill and die without adequate care. WHO Director-General Dr Tedros Ghebreyesus was direct: these disparities are not accidents of biology. They are consequences of choices, and therefore reversible.
Nearly four in ten cancer cases are preventable, driven by HPV, hepatitis B and C, tobacco, alcohol, obesity, and physical inactivity. Lung cancer remains the leading cause of cancer death worldwide, while breast, colorectal, and prostate cancers claim enormous tolls across genders.
Nigeria is attempting to change its trajectory. At a conference in Abuja this week, the National Institute for Cancer Research and Treatment announced an expansion of the Catastrophic Health Fund — a programme within the National Health Insurance Authority that now subsidises prevention, diagnosis, chemotherapy, and radiotherapy for eligible patients. A separate National Cancer Health Fund serves indigent patients who cannot afford care at all. These are not symbolic measures. They are direct attempts to dismantle the cost barriers that keep Nigerians from seeking treatment in time.
The government is also investing in local drug manufacturing and clinical trials. Immunotherapy drugs like Nivolumab and Keytruda — which can cost tens of thousands of dollars per course — are being offered free to eligible trial participants. The ambition is clear: domesticate expensive treatments, produce medicines locally, and bring global research into Nigerian clinics. Dr Lolade Adewale, Special Adviser on Research and Innovation to the Minister of State for Health, stressed the importance of expanding insurance coverage as a pillar of financial protection.
The challenge, however, remains immense. Africa contributes only 8% of global cancer research despite shouldering a growing share of the disease burden. Experts at the Abuja conference are working to identify which international findings can be adapted to African health systems — painstaking work, but essential. Without it, the projections are unambiguous: the gap between rich and poor will only deepen.
Every day, cancer kills more people than the population of a small city. The World Health Organisation released figures this week showing that globally, the disease claims over 26,000 lives daily—nearly 10 million deaths each year. The numbers are staggering, but the geography of those deaths tells a starker story still. A woman diagnosed with breast cancer in a wealthy country has an 87 percent chance of surviving five years. In a poor country, her odds drop to 42 percent. The same disease. Different worlds.
The WHO's 2026 Global Status Report on Cancer, produced jointly with the International Agency for Research on Cancer, paints a portrait of a disease that has become the second leading cause of death globally, behind only cardiovascular disease. Without intervention, the annual caseload is projected to nearly double by 2050, climbing from the current 20.6 million new diagnoses to close to 35 million. The burden is not evenly distributed. Asia carries more than half of all cases and deaths. Europe, with only nine percent of the world's population, accounts for 21 percent of global cancer cases and 20 percent of deaths. Africa and parts of Asia, meanwhile, see lower incidence rates but disproportionately high mortality—the signature of a region where people get sick and die without adequate care.
Lung cancer remains the leading cause of cancer death worldwide. Among men, prostate and colorectal cancers are also common killers. Women face a different burden: breast, lung, and colorectal cancers account for a substantial share. Yet nearly four in ten of these cases are preventable. Human papillomavirus, hepatitis B and C, tobacco, alcohol, obesity, and sedentary living drive much of the disease. The inequities documented in the report are not accidents of biology. They are, as WHO Director-General Dr Tedros Ghebreyesus put it, consequences of choices—and therefore reversible through unified action.
Nigeria is attempting to reverse course. At a conference in Abuja this week, the National Institute for Cancer Research and Treatment announced that the Federal Government has expanded financial support for cancer patients. The Catastrophic Health Fund, housed within the National Health Insurance Authority, now subsidises prevention, diagnosis, chemotherapy, and radiotherapy for eligible patients. NICRAT manages a separate National Cancer Health Fund for indigent patients unable to afford care. These are not symbolic gestures. They are direct attempts to remove the cost barrier that keeps Nigerians from seeking treatment.
But money alone is not enough. The government is also investing in local drug production and clinical trials. Drugs like Nivolumab and Keytruda, which can cost tens of thousands of dollars per course, are now being provided free through clinical trials to eligible participants. The strategy is deliberate: domesticate expensive treatments, produce medicines locally, translate global research into action in Nigerian clinics. The goal is to keep Nigerians from having to travel abroad for care they cannot afford at home.
Dr Lolade Adewale, Special Adviser on Research and Innovation to the Minister of State for Health, emphasised that the government is strengthening financial protection through expanded insurance coverage. Yet the scale of the challenge is immense. Africa contributes only eight percent of global cancer research despite carrying a significant share of the global disease burden. The continent is simultaneously the place where cancer is rising fastest and where the tools to fight it are thinnest on the ground. Experts at the Abuja conference are examining landmark studies from recent international meetings, asking which ones can be adapted to African health systems. The work is painstaking and urgent. Without it, the projections suggest, the gap between rich and poor will only widen.
Notable Quotes
Whether a person survives cancer should never depend on where they were born or what they earn— WHO Director-General Dr Tedros Ghebreyesus
What we are trying to do is domesticate expensive treatments by producing much-needed medicines locally and translating global research into actions in our clinics— Prof. Usman Malami, Director-General of the National Institute for Cancer Research and Treatment
The Hearth Conversation Another angle on the story
Why does a woman's survival rate for breast cancer drop from 87 percent to 42 percent just because she was born in a poor country?
It's not the cancer that changes. It's everything else—whether she can afford screening, whether chemotherapy is available where she lives, whether she can take time off work for treatment, whether the drugs are even in her country. In wealthy places, all of that infrastructure exists. In poor places, it often doesn't.
The WHO report says these inequities are "consequences of choices." What choices are being made?
Choices about where to invest research money, where to build treatment facilities, which drugs to manufacture locally versus import. Choices about whether cancer care is included in health insurance. Right now, fewer than one in three countries include it in their universal health coverage. That's a choice.
Nigeria is trying something different—local drug production, financial assistance programs. Will that actually work?
It's a start. If you can produce expensive drugs locally, the cost drops dramatically. If you remove the financial barrier through subsidies and insurance, more people seek treatment earlier. But it takes time, and the infrastructure has to be built from scratch in many places.
Africa contributes only eight percent of global cancer research. Why is that a problem?
Because research done in wealthy countries doesn't always translate to African contexts. The cancers are different, the populations are different, the resources are different. You need local research to understand local disease and build local solutions.
The report projects 35 million new cases by 2050. Is that inevitable?
No. That's the point of the WHO report. Nearly four in ten cases are preventable through vaccination, tobacco control, and lifestyle changes. The trajectory isn't fixed. But it requires action now.